Latest Healthcare News

Hydrix has landed a A$3.4 million contract with US-based Remedy Robotics to develop safety-critical software and embedded electronics for the N1 robotic system, marking a major step in its medical robotics ambitions.

Imricor Medical Systems has submitted its final 510(k) devices to the FDA, marking a major step towards commercialising its MRI-guided cardiac catheterisation platform in the US.

PainChek appoints seasoned US medtech executive Karen Holzberger as CEO to spearhead growth following FDA clearance and major US contracts.

OncoSil Medical has gained Saudi FDA approval for its OncoSil™ device, enabling full reimbursement and commercial access in Saudi Arabia, the Middle East's largest healthcare market.

ECS Botanics delivered a fourth consecutive quarter of positive operating cash flow in Q4 FY26, with a full-year turnaround of $5.9 million. The company’s branded B2C revenue surged 31% year-on-year, supported by product launches and European market expansion.

LTR Pharma has formalised its US commercialisation strategy by signing a definitive agreement with telehealth leader Shed, targeting at least 150,000 ROXUS units in the first year through digital men’s health platforms.

TrivarX has locked in investigational product supply critical for starting its Phase 1 clinical trial of the Stabl-Im MRI imaging platform, targeting a 2026 trial commencement.

Chimeric Therapeutics reports encouraging interim data from its Phase 1/2 trial of CHM CDH17 CAR-T therapy, with tumour shrinkage up to 40% and stable disease maintained for months at the highest dose level.

Microba Life Sciences has delivered robust FY26 growth in its core microbiome testing business, with revenues up 92% year-on-year and a new GI Navigator product set for launch in September 2026. The company also announced a $7 million annualised cost reduction program as it advances towards cashflow break-even.

Memphasys delivered a record $150,000 quarterly revenue, secured its largest Felix™ supply contract with Monash IVF, and expanded into UK and Southeast Asian IVF markets, positioning for accelerated growth in FY27.

Neurotech International has locked in a $3.15 million secured loan against its anticipated R&D tax incentives to fund pivotal Phase III autism trials and ongoing operations.

EMVision Medical Devices has hit key enrolment milestones in its pivotal brain scanner trial, expanded clinical endpoints, and maintained a strong cash position with $17.1 million on hand.